不同化疗方案对早期乳腺癌患者,低HER-2表达的不同化疗方案的影响
Yurui Xu1, Lin Chao2, Jianyu Wang3
1Yurui Xu, Department of Breast and Thyroid, Wuxi No.2 People's, Hospital Affiliated Nanjing Medical University, Wuxi 214002, Jiangsu, China.
Pakistan journal of medical sciences
|September 8, 2023
概括
在低HER-2乳腺癌患者中,脂质体封装的多克索鲁比加环胺 (DC) 改善了免疫功能,并减少了副作用. 这种化疗方案的预后效益与多塞塔克塞尔加环胺 (TC) 相似.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 乳腺癌是一种异质性疾病,治疗反应不同.
- 人体表皮生长因子受体2 (HER-2) 低表达是一种特定的亚型,需要量身定制的治疗策略.
- 术后辅助化疗对于改善早期乳腺癌的预后至关重要.
研究的目的:
- 在低HER-2乳腺癌患者中比较两种化疗方案的疗效.
- 评估不同化疗方案对免疫功能的影响.
- 评估和比较治疗组之间的不良反应发生率.
主要方法:
- 60名乳腺癌患者的回顾性分析,HER-2表达低.
- 患者接受了聚乙烯糖醇涂层脂质体封装的多克索鲁比辛加环胺 (DC组) 或多塞塔克塞尔加环胺 (TC组).
- 预后,免疫标志物 (IgG,CD3+,CD4+,CD4+/CD8+) 和不良事件 (白血病,脱发,恶心,吐) 的比较.
主要成果:
- 治疗后,DC组的IgG,CD4+和CD4+/CD8+水平增加,与TC组不同,TC组的IgG,CD4+和CD8+水平下降 (P<0.05).
- 免疫标志物 (IgG,CD4+,CD4+/CD8+) 在DC组与TC组相比,在治疗后显著改善 (P<0.05).
- 与TC疗法相比,DC疗法导致白血病,脱发,恶心和吐的发生率显著降低 (P<0.05).
结论:
- 体封装的多克索鲁比加环胺 (DC) 增强免疫功能,减少低HER-2乳腺癌患者的不良反应.
- 对这些患者来说,DC疗程的预后效益与多塞塔克塞尔加环胺 (TC) 的预后效益相当.
- DC化疗代表了管理早期,低HER-2乳腺癌手术后的有利选择.
相关概念视频
02:49Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
237
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
237